AGP Executive Report
Last update: 2 hours agoLife-Science Instrumentation Demand: ADInstruments points to sustained growth in life science instrumentation, with data acquisition software set to lead market expansion as labs modernize and replace siloed toolchains. AI Governance Meets Industry: Trump and House Speaker Mike Johnson plan a White House meeting with top AI CEOs amid rising fears over AI agent security risks and calls for guardrails. China’s Publishing Power Play: China launched a state-backed, no article-fee science journal, Vita, aiming to boost domestic influence over what counts as “high-quality” research. Metabolic Drug Deal: Novo Nordisk licensed HRS-1596 from Hengrui Pharma in a deal worth up to $2.6B, betting on a once-weekly oral GLP-1/GIP approach. Obesity Trial Update: Novo’s CagriSema showed stronger weight loss than tirzepatide in late-stage results, reinforcing the race for next-gen obesity drugs. Healthcare Tech in Practice: Japan’s AI-assisted medical services gain broad support in a new survey, while a Canadian utility deploys satellite + AI vegetation risk management to cut operational uncertainty. Biotech Ops & Policy: PhRMA names Eric Cantor as CEO, and the APHIS comment process begins for deregulating certain genetically engineered cotton varieties.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Advancing Patient Care Through Pharma-Sponsored Programs]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/28944112-946148658-e9970e8ca11ecf6ec2c7775aa8df59d14b880065-2842x1608-200x113.png)
